Reviews/TNF Alpha Inhibitors/TNF-alpha inhibitors inhibit radiographic joint damage progression in RA
· TN-RA-03 · v2
The evidence here points one way: in patients with rheumatoid arthritis, adding a TNF-alpha inhibitor to methotrexate is associated with less visible joint damage on X-rays over time. Two separate drugs show this when compared against a non-TNFi control, and real-world registry and cohort data show that joint damage barely advances in patients on these drugs. The effect is consistent in direction across settings, which is why the panel treated the claim as well supported. But the two comparative analyses were done after the trials finished rather than being designed up front to measure X-ray damage, and the registry patients had no untreated comparison group, so some of the benefit cannot be cleanly separated from methotrexate, tight treatment targets, or the natural course of disease. The magnitude of the measured advantage is also modest, since many control patients also had no progression.
Two independent TNFi agents carry comparative radiographic data in the same direction: in OPTIMA, adalimumab plus methotrexate produced radiographic non-progression in 86% of patients versus 72% on methotrexate monotherapy at weeks 52 and 78 [17], and in ASPIRE infliximab plus methotrexate showed generally smaller proportions of damaged joints than placebo plus methotrexate across 870 hand radiographs [5]. Registry and cohort data describe very low absolute progression under TNFi: in the DANBIO registry of 930 anti-TNF-treated patients the median change in total Sharp score was 0.0 units per year and 27% progressed [7], and pooled trial data placed 86% of 1887 patients in a stable-score cluster [1]. A treat-to-target elderly-onset cohort achieved structural remission in 49.7% of patients, with 31.0% on a TNFi at week 52 [19]. Together these describe inhibition of radiographic progression under TNFi, though only [17] and [5] carry a comparator. The contested point: The division is whether the low progression seen under TNFi can be attributed to the drug itself. The two comparative papers [17][5] are both post-hoc analyses without a pre-specified radiographic primary endpoint, and the supporting cohorts [1][7][19] have no non-TNFi arm, so concomitant methotrexate, treat-to-target strategy and natural history remain confounded with the TNFi effect.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from TNF Alpha Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The cohort/registry support ([1], [7], [19]) has no non-TNFi comparator arm, so low progression cannot be attributed to TNFi rather than concomitant MTX, treat-to-target strategy, or natural history.
The two comparative papers [17] and [5] are both post-hoc analyses, not trials with a pre-specified radiographic primary endpoint, raising risk of selective reporting of the favourable radiographic result.
Where it remains uncertain. Both comparative analyses [17][5] are post-hoc rather than radiographic-primary trials, and the cohort support [1][7][19] has no non-TNFi comparator, so the benefit cannot be fully separated from methotrexate and treatment strategy.
Aleatory
Even under TNFi, progression is heterogeneous: 27% of DANBIO patients progressed [7] and distinct trajectory clusters exist including a relentless-progression group [1], so individual outcomes vary irreducibly.
Epistemic
The corpus holds no pre-specified placebo-controlled TNFi trial with a radiographic primary endpoint; the comparative evidence [17][5] is entirely post-hoc, leaving selective-reporting risk unresolved.
Inferential
TNFi was given with methotrexate and under treat-to-target strategies [19], so attributing the low progression specifically to TNFi rather than methotrexate or strategy requires an inferential leap the corpus does not close.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pooled TNFi-RCT data showing the large majority of treated patients have stable radiographic scores over 2 years.
“one with a stable SHS over the whole 2-year period (C0/lowChange; 86%)”
Panel auditInternal validity: medium · scope of inference: Patterns of radiographic damage accrual over 2 years in RA patients treated with TNF inhibitors.Key limitations: no non-TNFi comparator · descriptive clustering only · post hoc
Infliximab+MTX vs placebo+MTX comparison showing less radiographic damage with the TNFi arm.
“the proportions of joints with damage at week 54 were generally larger in the placebo plus MTX group”
Panel auditInternal validity: medium · scope of inference: Joint-level development and progression of radiographic damage over 54 weeks in early active RA, infliximab+MTX versus placebo+MTX.Key limitations: post hoc analysis · no reported significance for treatment contrast · descriptive comparison
Clinical-practice registry quantifying very low radiographic progression during TNFi treatment.
“ΔTSS was median 0.0 [0.0-0.5 IQR/mean 0.6 (SD 2.4)] units/year”
Panel auditInternal validity: medium · scope of inference: Predictors of radiographic progression over ~2 years in TNFi-treated RA in clinical practice.Key limitations: no non-TNFi comparator · observational confounding by indication for stopping
3 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, significant comparative radiographic benefit across two TNFi plus supportive cohort data, but limited to post-hoc analyses with modest effect sizes and no dedicated primary radiographic trial in the corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No pre-specified radiographic-primary TNFi RCT. Both comparative analyses [17][5] are post-hoc, so the favourable radiographic result cannot be separated from selective reporting. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-plus-methotrexate controlled TNFi trial with radiographic progression (Sharp/van der Heijde change) as the pre-registered primary endpoint.
Open question: Does a TNFi produce less radiographic progression than a non-TNFi comparator when progression is the pre-specified primary endpoint? Why it is still open: The only comparative data in the corpus [17][5] are post-hoc analyses with no radiographic-primary design.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19